We use cookies and other data for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.
Add this topic to your myFT Digest for news straight to your inbox
A greater focus on innovation should top the UK pharma chief executive’s agenda
Emma Walmsley believes listing of consumer health business will strengthen pharma division
As split nears completion, investors turn attention to what comes next
Hedge fund is pushing for chief executive Emma Walmsley to reapply for her job
UK pharma group has teamed up with South Korea’s SK Bioscience on jab that uses its adjuvant technology
Demand for jabs for meningitis, diphtheria and hepatitis recovers after pandemic disruption
Pharma group’s board backs Emma Walmsley and announces deal for brain disease drug
Activist hedge fund has outlined little more than polite introduction with air of menace
Activist fund seeks refreshed board to pick who runs UK drugmaker after consumer health spin-off
Emma Walmsley insists she is a ‘change agent’ committed to transforming pharma group
Pharma investors eager to be shot of consumer unit will retain exposure without the upsides
Walmsley has questions to answer at roadshow over direction of pharma group’s future
Emma Walmsley says drugmaker’s pipeline shows ‘real progress’
It has quietly built up a multibillion-dollar stake in the struggling drugmaker
CEO Emma Walmsley under scrutiny as British drugmaker’s cupboard looks increasingly bare
Moncef Slaoui forced out as chair of the board of drugmaker’s subsidiary Galvani Bioelectronics
UK group says treatments for diseases other than Covid-19 have picked up after lockdown disruption
Covid-19 is a warning that we must develop drugs to treat future threats
UK drugmaker hopes to launch clinical trial by end of the year
UK drugmaker also boosted by performance of consumer health and vaccines divisions
Bold decisions being taken by chief executive Emma Walmsley should pay off
The CEO has lost no time in ruthlessly reshaping the health and pharmaceuticals group
Cash influx intended to bolster search for blockbuster drugs and dealmaking
Shares lose 7 per cent on news of drugmaker’s first big acquisition under Emma Walmsley
International Edition
